- Home
- LIEN vs YMAB Comparison
LIEN vs YMAB Comparison
Compare LIEN & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIEN
- YMAB
- Stock Information
- Founded
- LIEN 2021
- YMAB 2015
- Country
- LIEN United States
- YMAB United States
- Employees
- LIEN N/A
- YMAB N/A
- Industry
- LIEN
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LIEN
- YMAB Health Care
- Exchange
- LIEN NYSE
- YMAB Nasdaq
- Market Cap
- LIEN 234.6M
- YMAB 218.4M
- IPO Year
- LIEN 2022
- YMAB 2018
- Fundamental
- Price
- LIEN $10.10
- YMAB $4.04
- Analyst Decision
- LIEN Hold
- YMAB Buy
- Analyst Count
- LIEN 1
- YMAB 11
- Target Price
- LIEN N/A
- YMAB $18.73
- AVG Volume (30 Days)
- LIEN 16.8K
- YMAB 204.4K
- Earning Date
- LIEN 05-14-2025
- YMAB 05-13-2025
- Dividend Yield
- LIEN 13.59%
- YMAB N/A
- EPS Growth
- LIEN N/A
- YMAB N/A
- EPS
- LIEN 0.93
- YMAB N/A
- Revenue
- LIEN $21,665,753.00
- YMAB $87,685,000.00
- Revenue This Year
- LIEN $102.44
- YMAB N/A
- Revenue Next Year
- LIEN N/A
- YMAB $18.83
- P/E Ratio
- LIEN $10.77
- YMAB N/A
- Revenue Growth
- LIEN 81.56
- YMAB 3.38
- 52 Week Low
- LIEN $9.71
- YMAB $3.84
- 52 Week High
- LIEN $13.38
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- LIEN N/A
- YMAB 42.87
- Support Level
- LIEN N/A
- YMAB $4.02
- Resistance Level
- LIEN N/A
- YMAB $4.60
- Average True Range (ATR)
- LIEN 0.00
- YMAB 0.32
- MACD
- LIEN 0.00
- YMAB -0.01
- Stochastic Oscillator
- LIEN 0.00
- YMAB 23.93
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.